Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement (2020)
Journal Article
Vankemmelbeke, M., McIntosh, R. S., Chua, J. X., Kirk, T., Daniels, I., Patsalidou, M., …Durrant, L. G. (2020). Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement. Cancer Research, 80(16), 3399-3412. https://doi.org/10.1158/0008-5472.CAN-19-3599

©2020 American Association for Cancer Research. Murine IgG3 glycan-targeting mAb often induces direct cell killing in the absence of immune effector cells or complement via a proinflammatory mechanism resembling oncotic necrosis. This cancer cell kil... Read More about Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer (2017)
Journal Article
Machado, L. R., Moseley, P. M., Moss, R., Deen, S., Nolan, C. C., Spendlove, I., …Durrant, L. (2017). High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget, https://doi.org/10.18632/oncotarget.20538

High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour types where expression regulates tumour cell growth and survival. We hypothesised that high HMGB1 expression in ovarian tumours would predict poor patient survival. Using... Read More about High mobility group protein B1 is a predictor of poor survival in ovarian cancer.

Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity (2015)
Journal Article
Chua, J., Vankemmelbeke, M., McIntosh, R. S., Clarke, P. A., Moss, R., Parsons, T., …Durrant, L. (2015). Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity. Clinical Cancer Research, 21(13), 2963-2974. https://doi.org/10.1158/1078-0432.CCR-14-3030

© 2015 American Association for Cancer Research. Purpose: To produce antitumor monoclonal antibodies (mAbs) targeting glycans as they are aberrantly expressed in tumors and are coaccessory molecules for key survival pathways. Experimental Design: Two... Read More about Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity.